129409-53-6Relevant academic research and scientific papers
Thiazole compounds and methods of use
-
Page/Page column 63-64; 64, (2008/06/13)
The invention relates to thiazole compounds of Formula I and Formula II and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
Electrochemistry of some Ethyl α-Bromo(Dihalophenyl) Acetates and Electrochemical Synthesis of Diastereoisomeric Diethyl 2,3-Bis(dihalogenophenyl)Succinates
Mattiello, Leonardo,Luca, Carlo De,Rampazzo, Liliana
, p. 1041 - 1044 (2007/10/02)
Ethyl α-bromo-2,4- or -3,4-dihalogenophenylacetates (ABr), where halogen = F or Cl, are prepared and electrolysed on reticulated vitreous carbon (RVC) in dimethylformamide containing Et4NClO4 (0.1 mol dm-3).Potentiostatic reduction at E = -1.6 to -1.8 V versus SCE furnishes the corresponding racemic and meso succinates (AA) (13)-(16).Monoesters AH (5)-(8) are also isolated.An excess of racemic isomer is observed for (14), (15), and (16).Voltammetric experiments show practically no difference between the reduction potentials of the isomeric compounds.Diastereoisomers can be distinguished by NMR spectroscopy, allowing diastereoisomeric excess (de) to be evaluated before isolation of the single products.A mechanism involving radical intermediates A* cannot be excluded.On this basis, the des can be explained by assuming different geometries for A* when the phenyl group bears different substituents.
